$Subepicardial adipose genes contribute to the deterioration of heart failure preserved ejection fraction$

Subepicardial adipose genes contribute to the deterioration of heart failure preserved ejection fraction

BackgroundThe mortality of patients with acute myocardial infarction (MI) raised rapidly in last decade and obesity are becoming the major cause to CAD progression, thus inducing heart failure preserved ejection fraction (HFpEF). However, why visceral adipocytes show different effects on healthy and...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ruiying Zhang, Man Wang, Yuheng Lang, Jiaqi Zhang, Yuchao Wang, Han Zheng, Yue Zheng, Bingyang Zhou
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Series:	Frontiers in Cardiovascular Medicine
Subjects:	heart failure visceral adipocyte genes HFpEF SASPs macrophage human sub-epicardial tissues
Online Access:	https://www.frontiersin.org/articles/10.3389/fcvm.2025.1501397/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of severe obesity on exercise performance in heart failure with preserved ejection fraction
by: Satyam Sarma, et al.
Published: (2020-11-01)

Epicardial Adipose Tissue and Heterogeneity Parameters Combined with Inflammatory Cells to Predict the Value of Heart Failure with Preserved Ejection Fraction Patients Post Myocardial Infarction
by: Yu-jiao Song, et al.
Published: (2025-05-01)

Hospitalized patients and stimulant use-associated heart failure: importance of ejection fraction and related risk factors
by: Akshat Agrawal, et al.
Published: (2025-07-01)

Small Heart Size and Premature Death in 366,484 Individuals With Normal Ejection Fraction
by: Stephanie J. Rowe, BBiomed, MD, et al.
Published: (2025-01-01)

Cardiometabolic heart failure with preserved ejection fraction: from molecular signatures to personalized treatment
by: Era Gorica, et al.
Published: (2025-07-01)

Clinical profile of heart failure in geriatric patients in a tertiary cardiac hospital of Bangladesh
by: Mahbuba Yesmin, et al.
Published: (2025-06-01)

Cardiopulmonary exercise testing as a prognosis‐assessing tool in heart failure with preserved ejection fraction
by: C. Rozados daConceicao, et al.
Published: (2025-06-01)

Impact of Voluntary Exercise on Systemic Inflammation in a 2‐Hit Model of Heart Failure With Preserved Ejection Fraction
by: Heather Quiriarte, et al.
Published: (2025-02-01)

Differential Effects of Landiolol in Patients with Atrial Fibrillation and Atrial Tachycardia
by: Kengo Ayabe, et al.
Published: (2024-10-01)

Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
by: Mark Sweeney, et al.
Published: (2020-09-01)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction
by: Shuo Xu, et al.
Published: (2025-04-01)

Exploring the Noninvasive Evaluation of the Pulmonary Pressure–Flow Relationship During Exercise
by: Mads J. Andersen, et al.
Published: (2024-08-01)

The Possible Role of Rosuvastatin Therapy in HFpEF Patients—A Preliminary Report
by: Tomasz Urbanowicz, et al.
Published: (2024-11-01)

Carbohydrate antigen-125 (CA125): a marker of right ventricular dysfunction and poor prognosis in heart failure with preserved ejection fraction
by: Sher May Ng, et al.
Published: (2025-10-01)

Identification of ageing-associated gene signatures in heart failure with preserved ejection fraction by integrated bioinformatics analysis and machine learning
by: Guoxing Li, et al.
Published: (2025-07-01)

Real‐world clinical diagnostics of heart failure patients with reduced or preserved ejection fraction
by: Jenni Huusko, et al.
Published: (2020-06-01)

Multi‐microRNA diagnostic panel for heart failure with preserved ejection fraction in preclinical and clinical settings
by: Reza Parvan, et al.
Published: (2025-08-01)

Multiparity induces persistent myocardial structural, functional and transcriptomic remodelling in mice
by: Ruth R. Magaye, et al.
Published: (2025-07-01)

A higher mortality in men compared to women with heart failure in primary care and ejection fraction equal to or more than 40%
by: Björn Eriksson, et al.
Published: (2024-12-01)

The Role of Inflammation in the Pathophysiology of Heart Failure
by: Marwan Amara, et al.
Published: (2025-07-01)

Intravenous iron in heart failure: still no prognostic impact, but questions remain
by: Ibrahim El-Battrawy, et al.
Published: (2025-08-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction
by: L. Healy, et al.
Published: (2025-04-01)

Incidence and risk factors of heart failure with preserved ejection fraction in elderly patients with hypertension
by: Min Chen, et al.
Published: (2024-12-01)

Variation in clinical and patient‐reported outcomes among complex heart failure with preserved ejection fraction phenotypes
by: Kelsey M. Flint, et al.
Published: (2020-06-01)

Schaftoside improves HFpEF through regulation the autophagy-lysosome pathway by allosterically targeting CaMKII-δ
by: Haiying Zhang, et al.
Published: (2024-12-01)

Association of Kidney Function With Incident Heart Failure: An Analysis of the Women's Health Initiative
by: Richard K. Cheng, et al.
Published: (2025-03-01)

Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-05-01)

Phenotyping patients with chronic obstructive pulmonary disease and heart failure
by: Peter Moritz Becher, et al.
Published: (2025-04-01)

Correction: Adverse effects of finerenone in patients with heart failure: a systematic review and meta-analysis
by: Wanqian Yu, et al.
Published: (2025-07-01)

EVOLUTION‐HF DEallEF: A non‐interventional study of patients with heart failure initiated on dapagliflozin: study design
by: Matthias Paul, et al.
Published: (2025-08-01)

Novel Relaxin Receptor RXFP1 Agonist AZD3427 in the Treatment of Heart Failure: A Phase 1a/b, First‐in‐Human, Randomized, Single‐Blind, Placebo‐Controlled Study
by: Kathleen Connolly, et al.
Published: (2024-08-01)

The gut microbiota-inflammation-HFpEF axis: deciphering the role of gut microbiota dysregulation in the pathogenesis and management of HFpEF
by: Shenghua Zhou, et al.
Published: (2025-03-01)

Prognostic and predictive microRNA panels for heart failure patients with reduced or preserved ejection fraction: a meta-analysis of Kaplan–Meier-based individual patient data
by: Reza Parvan, et al.
Published: (2025-07-01)

Nitazoxanide protects against heart failure with preserved ejection and metabolic syndrome induced by high-fat diet (HFD) plus L-NAME “two-hit” in mice
by: Jiahui Chen, et al.
Published: (2025-03-01)

Chronotropic Incompetence and Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
by: Ting‐Tse Lin, et al.
Published: (2025-07-01)

Comprehensive exploration of unexplained dyspnoea in subjects with normal ejection fraction and low natriuretic peptides
by: Emmanuelle Berthelot, et al.
Published: (2025-04-01)

Relation of left atrial overload indices with prognostic endpoints in heart failure and preserved ejection fraction
by: Shiro Hoshida, et al.
Published: (2022-06-01)

Limited Ventilatory Reserve During Exercise in Heart Failure with Preserved Ejection FractionTake-Home Points
by: Gizem Cifci, MD, et al.
Published: (2025-09-01)

Atrial Fibrillation, Heart Failure Phenotypes, and Mortality Risk in the Nationwide START Registry: A Propensity Score Matching Analysis
by: Danilo Menichelli, et al.
Published: (2025-06-01)